Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure

References

• Kasper F, Hauser L, Jameson L. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2015.
   Google Scholar
• Morrissey RP, Czer L, Shah PK. Chronic heart failure. Am J Cardiovasc Drugs. 2011;11(3):153–171. doi:10.2165/11592090-000000000-0000021619379
   PubMed Web of Science ®Google Scholar
• Tziakas DN, Chalikias GK, Xatseras DI. Neurohormonal hypothesis in heart failure. Hellenic J Cardiol. 2003;44:195–205.
   Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199. doi:10.1161/01.CIR.0000035653.72855.BF12390947
   PubMed Web of Science ®Google Scholar
• Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007;104(1):282–287. doi:10.1073/pnas.060685410417185418
   PubMed Web of Science ®Google Scholar
• Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2):103. doi:10.1038/nri269220081870
   PubMed Web of Science ®Google Scholar
• Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL‐33 and KSHV for attachment to chromatin through the H2A–H2B acidic pocket. EMBO Rep. 2008;9(10):1006–1012. doi:10.1038/embor.2008.14518688256
   PubMed Web of Science ®Google Scholar
• Miller AM, Liew FY. The IL-33/ST2 pathway—a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131(2):179–186. doi:10.1016/j.pharmthera.2011.02.00521356240
   PubMed Web of Science ®Google Scholar
• Trajkovic V, Sweet MJ, Xu D. T1/ST2—an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004;15(2–3):87–95. doi:10.1016/j.cytogfr.2004.02.00415110792
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–490. doi:10.1016/j.immuni.2005.09.01516286016
   PubMed Web of Science ®Google Scholar
• Tago K, Noda T, Hayakawa M, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285(5):1377–1383. doi:10.1006/bbrc.2001.530611478810
   PubMed Web of Science ®Google Scholar
• Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384(1):105–109. doi:10.1016/j.bbrc.2009.04.08119393621
   PubMed Web of Science ®Google Scholar
• Pusceddu I, Dieplinger B, Mueller T. ST2 and the ST2/IL-33 signalling pathway–biochemistry and pathophysiology in animal models and humans. Clin Chim Acta. 2019;495:493–500. doi:10.1016/j.cca.2019.05.02331136737
   PubMed Web of Science ®Google Scholar
• Aleksova A, Paldino A, Beltrami AP, et al. Cardiac biomarkers in the emergency department: the role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome—there is meat on the bone. J Clin Med. 2019;8(2):270. doi:10.3390/jcm8020270
   Web of Science ®Google Scholar
• Coronado MJ, Bruno KA, Blauwet LA, et al. Elevated sera sST 2 is associated with heart failure in men≤ 50 years old with myocarditis. J Am Heart Assoc. 2019;8(2):e008968. doi:10.1161/JAHA.118.00896830638108
   PubMed Web of Science ®Google Scholar
• Lotierzo M, Dupuy AM, Kalmanovich E, Roubille F, Cristol JP. sST2 as a value-added biomarker in heart failure. Clin Chim Acta. 2020;501:120–130. doi:10.1016/j.cca.2019.10.02931678574
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–1549. doi:10.1172/JCI3063417492053
   PubMed Web of Science ®Google Scholar
• Human Sst2(Soluble ST2) ELISA Kit; 2017 7th Availabe from: www.elabscience.com.
   Google Scholar
• Ab119547– IL-33 Human ELISA Kit; 2018 Availabe from: www.abcam.com.
   Google Scholar
• Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997;29(5):1060–1066. doi:10.1016/S0735-1097(97)00012-09120160
   PubMed Web of Science ®Google Scholar
• Group MHS. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi:10.1016/S0140-6736(99)04440-210376614
   PubMed Web of Science ®Google Scholar
• Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25(5):1154–1161. doi:10.1016/0735-1097(94)00543-Y7897129
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2(1):65–72. doi:10.1016/j.jchf.2013.10.00524622120
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2(6):684–691. doi:10.1161/CIRCHEARTFAILURE.109.87324019919994
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–2966. doi:10.1161/01.CIR.0000038705.69871.D912460879
   PubMed Web of Science ®Google Scholar
• Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):2186–2190. doi:10.1161/01.CIR.0000127958.21003.5A15117853
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936–1944. doi:10.1161/CIRCULATIONAHA.107.72802218378613
   PubMed Web of Science ®Google Scholar
• Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–250. doi:10.1016/j.jacc.2009.08.04720117403
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Pascual-Figal D, Januzzi JL, et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Revista española de cardiología. 2010;63(10):1171–1178. doi:10.1016/S1885-5857(10)70231-020875357
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259–267. doi:10.1016/j.amjcard.2010.09.01121211603
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2012;209(13):2515. doi:10.1084/jem.2007186820913c
   Web of Science ®Google Scholar
• Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol. 2011;7(6):321. doi:10.1038/nrrheum.2011.5321519352
   PubMed Web of Science ®Google Scholar
• Yndestad A, Marshall AK, Hodgkinson JD, Sugden PH, Clerk A. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. Int J Biochem Cell Biol. 2010;42(2):263–272. doi:10.1016/j.biocel.2009.10.02119861169
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A, McCrink K, Brill A. Impact of CYP2D6 genetic variation on the response of the cardiovascular patient to carvedilol and metoprolol. Curr Drug Metab. 2015;17(1):30–36. doi:10.2174/138920021766615110512542526537419
   PubMed Web of Science ®Google Scholar
• Parker BM, Rogers SL, Lymperopoulos A. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle. Future Med. 2018;1089–1093.
   Google Scholar